Results of concomitant groin-free percutaneous temporary RVAD support using a centrifugal pump with a double-lumen jugular venous cannula in LVAD patients

被引:21
|
作者
Schmack, Bastian [1 ]
Farag, Mina [1 ]
Kremer, Jamila [1 ]
Grossekettler, Leonie [2 ]
Brcic, Andreas [3 ]
Raake, Philip W. [2 ]
Kreusser, Michael M. [2 ]
Goldwasser, Ranny [1 ]
Popov, Aron-Frederik [4 ]
Mansur, Ashham [5 ]
Karck, Matthias [1 ]
Ruhparwar, Arjang [1 ]
机构
[1] Univ Hosp Heidelberg, Dept Cardiac Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Dept Internal Med 3, Cardiol, Angiol,Pneumol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Dept Anaesthesiol, Heidelberg, Germany
[4] Univ Hosp Tubingen, Dept Thorac & Cardiovasc Surg, Tubingen, Germany
[5] Univ Goettingen, Univ Med Ctr, Dept Anesthesiol Emergency & Intens Care Med, Gottingen, Germany
关键词
INTERMACS; heart failure (HF); left ventricular assist device (LVAD); right ventricular failure; ProtekDuo; VENTRICULAR ASSIST DEVICE; RIGHT HEART-FAILURE; RISK SCORE; IMPLANTATION; VALIDATION; OUTCOMES;
D O I
10.21037/jtd.2018.11.121
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Modern left ventricular assist devices (LVAD) have evolved to become standard of care in severe heart failure (HF) patients. Right HF (RHF) is a major complication responsible for early mortality. Several techniques for temporary right ventricular assist device (t-RVAD) have been described before, baring relevant disadvantages such as limited mobilization or the need for re-thoracotomy. We describe the results of an alternative technique for t-RVAD using the Tandem Heart (TM) with ProtekDuo (TM) cannula. Methods: An institutional retrospective single centre outcome analysis was performed including all permanent LVAD recipients with concomitant groin-free t-RVAD support. Results: Between October 2015 and September 2017, 11 patients (10 male, 90.9%) were included. Preoperative NYHA class was 3.8 +/- 0.75 and INTERMACS class 3.5 +/- 1.5. Four (36.4%) patients were already on mechanical circulatory support (MCS) at time of implantation with 4 (36.4%) patients already on inotropic support. All LVAD implantations were performed on-pump and 3 cases (27.3%) were re-do cases. Mean t-RVAD duration was 16.8 +/- 9.5 days. Ten patients (90.9%) could be weaned from temporary RVAD support, 1 patient deceased on support. Mean ICU stay was 23.8 +/- 16.5 days, while 30-day survival was 72.7%. Follow-up was complete with 214.7 +/- 283 days. Three patients (27.3%) died following multi-organ failure (MOF), 1 patient (9.1%) following intracranial bleed 12 days after t-RVAD explantation. No severe t-RVAD associated complications were observed. Conclusions: Our technique allows for safe groin-free t-RVAD providing all advantages of percutaneous implantation including complete mobilization and bedside explantation without any need for operation.
引用
收藏
页码:S913 / S920
页数:8
相关论文
共 1 条
  • [1] Results of Concomitant Percutaneous Temporary RVAD Support Using the Cardiac Assist TandemHeart With ProtekDuo Cannula in LVAD Patients
    Schmack, B.
    Kremer, J.
    Brcic, A.
    Grossekettler, L.
    Goldwasser, R.
    Arif, R.
    Farag, M.
    Schmidt, H.
    Kreusser, M.
    Raake, P. W.
    Karck, M.
    Ruhparwar, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S375 - S376